Huntington’s disease: pathogenesis to animal models
暂无分享,去创建一个
[1] S. Zeitlin,et al. Expression of the Huntingtin-associated protein 1 gene in the developing and adult mouse , 2000, Neuroscience Letters.
[2] P. Trzepacz,et al. Huntington's disease: Correlations of mental status with chorea , 1987, Biological Psychiatry.
[3] W. Maragos,et al. Neuronal cell death in Huntington’s disease: a potential role for dopamine , 2000, Trends in Neurosciences.
[4] Claire-Anne Gutekunst,et al. A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.
[5] M. Folstein. Heterogeneity in Alzheimer's disease , 1989, Neurobiology of Aging.
[6] C. Cepeda,et al. Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.
[7] A. Cooper,et al. The selective vulnerability of striatopallidal neurons , 1999, Progress in Neurobiology.
[8] F. Zitman,et al. Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena , 2001, European Psychiatry.
[9] F. Pedata,et al. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow , 2004, Neurobiology of Disease.
[10] S. Folstein,et al. Abnormal ocular motor control in Huntington's disease , 1983, Neurology.
[11] Marian DiFiglia,et al. Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.
[12] F. Darley,et al. Language changes after neurosurgery for parkinsonism , 1975, Brain and Language.
[13] J. Linden,et al. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum , 2001, The Journal of comparative neurology.
[14] Françoise Condé,et al. Replicating Huntington's disease phenotype in experimental animals , 1999, Progress in Neurobiology.
[15] C. Golden,et al. Neuropsychological deficits in early, middle, and late stage Huntington's disease as measured by the Luria-Nebraska Neuropsychological Battery. , 1981, The International journal of neuroscience.
[16] M. Chiang,et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model , 2005, Journal of neurochemistry.
[17] K. Heathfield. Huntington's chorea. Investigation into the prevalence of this disease in the area covered by the North East Metropolitan Regional Hospital Board. , 1967, Brain : a journal of neurology.
[18] J. Bolam,et al. GABAB receptors at glutamatergic synapses in the rat striatum , 2005, Neuroscience.
[19] G. Reynolds,et al. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain , 1987, Neuroscience Letters.
[20] R. Yasuda,et al. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. , 2003, Brain : a journal of neurology.
[21] D. Charvin,et al. À la recherche d’un rôle de la dopamine dans la maladie de Huntington , 2006 .
[22] E. Giacobini,et al. Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease , 1990, Journal of Neurology.
[23] Carlos Cepeda,et al. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect , 2004, Trends in Neurosciences.
[24] S. Folstein,et al. Huntington's disease as a model for mood disorders. Clues from neuropathology and neurochemistry. , 1990, Molecular and chemical neuropathology.
[25] J. Penney,et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.
[26] D. Tagle,et al. Recent advances in understanding the pathogenesis of Huntington's disease , 1999, Trends in Neurosciences.
[27] H. Steinbusch,et al. Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation , 2001, Neuroscience.
[28] Nicola Pavese,et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. , 2003, Brain : a journal of neurology.
[29] G. Cohen,et al. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[30] Kenneth W. G. Heathfeeld. Huntington's chorea. Investigation into the prevalence of this disease in the area covered by the North East Metropolitan Regional Hospital Board. , 1967 .
[31] P. Calabresi,et al. Endogenous GABA mediates presynaptic inhibition of spontaneous and evoked excitatory synaptic potentials in the rat neostriatum , 1990, Neuroscience Letters.
[32] L. Murri,et al. Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype , 2008, Neuroscience Letters.
[33] R. Schwarcz,et al. Excitotoxic models for neurodegenerative disorders. , 1984, Life sciences.
[34] S. W. Davies,et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] N. Butters,et al. Comparison of the neuropsychological deficits associated with early and advanced Huntington's disease. , 1978, Archives of neurology.
[36] J. Coyle,et al. Inhibitors of GABA metabolism: Implications for Huntington's disease , 1977, Annals of neurology.
[37] B. Fredholm,et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.
[38] A. Parent,et al. Synaptic relationships between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey , 1994, The Journal of comparative neurology.
[39] D. Sax,et al. Increased rate of suicide among patients with Huntington's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.
[40] P. Nicotera,et al. Ca2+ signals and death programmes in neurons , 2005, Philosophical Transactions of the Royal Society B: Biological Sciences.
[41] M. Beal,et al. Oxidative Stress in Huntington's Disease , 1999, Brain pathology.
[42] M. Beal,et al. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[43] P. Calabresi,et al. Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons , 2006, Neurobiology of Disease.
[44] M. Brini,et al. Calcium Homeostasis and Mitochondrial Dysfunction in Striatal Neurons of Huntington Disease* , 2008, Journal of Biological Chemistry.
[45] M. Chesselet,et al. Apoptosis in Huntington's disease , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[46] N W Kowall,et al. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[47] S. Folstein,et al. Clinical correlates of dementia and disability in Huntington's disease. , 1984, Journal of clinical neuropsychology.
[48] K. Varani,et al. The FASEB Journal express article 10.1096/fj.00-0730fje. Published online March 5, 2001. Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin , 2022 .
[49] A. Graybiel. Neurotransmitters and neuromodulators in the basal ganglia , 1990, Trends in Neurosciences.
[50] C. Hebb. CNS at the cellular level: identity of transmitter agents. , 1970, Annual review of physiology.
[51] F. Squitieri,et al. Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation , 2006, Mechanisms of Ageing and Development.
[52] Patrik Brundin,et al. Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.
[53] A. Charara,et al. Pre- and postsynaptic localization of GABAB receptors in the basal ganglia in monkeys , 1999, Neuroscience.
[54] B. Hassel,et al. Selective Inhibition of the Tricarboxylic Acid Cycle of GABAergic Neurons with 3‐Nitropropionic Acid In Vivo , 1995, Journal of neurochemistry.
[55] G. Geminiani,et al. Relationship between motor and cognitive disorders in Huntington's disease , 1988, Journal of Neurology.
[56] Barry Halliwell,et al. Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.
[57] M. Rossor,et al. Ornithine aminotransferase in Huntington's disease , 1982, Brain Research.
[58] D. Riche,et al. A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon , 1990, Experimental Neurology.
[59] R. Roemer,et al. Patterns of intellectual deficit in Huntington's disease. , 1982, Journal of clinical neuropsychology.
[60] A. Rego,et al. Mechanisms of neurodegeneration in Huntington’s disease , 2008, European Journal of Neuroscience.
[61] Paul W Goldberg,et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. , 1994, The New England journal of medicine.
[62] M. Giordano,et al. The quinolinic acid model of Huntington's disease: Locomotor abnormalities , 1989, Experimental Neurology.
[63] M. Morelli,et al. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications , 2007, Progress in Neurobiology.
[64] T. Perry,et al. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. , 1973, The New England journal of medicine.
[65] A. Tobin,et al. GABA signalling: therapeutic targets for epilepsy, Parkinson’s disease and Huntington’s disease , 2001, Expert opinion on therapeutic targets.
[66] Alf. L. Ørbeck. An Early Description of Huntington's Chorea , 1959, Medical History.
[67] A. Hackam,et al. Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3 , 2000, The Journal of Neuroscience.
[68] M. Beal,et al. Experimental therapeutics in transgenic mouse models of Huntington's disease , 2004, Nature Reviews Neuroscience.
[69] U. Ungerstedt,et al. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[70] T. Roberts. 3-Nitropropionic Acid Model of Metabolic Stress , 2005 .
[71] J. Penney,et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.
[72] H. Yin,et al. The role of the basal ganglia in habit formation , 2006, Nature Reviews Neuroscience.
[73] R J Leigh,et al. The measurement of abnormal movement: methods developed for Huntington's disease. , 1983, Neurobehavioral toxicology and teratology.
[74] M. Vidailhet,et al. Physiopathologie de la maladie de Huntington : état des connaissances , 2008 .
[75] J. Cummings,et al. Behavioral and psychiatric symptoms associated with Huntington's disease. , 1995, Advances in neurology.
[76] Virginia E. Papaioannou,et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue , 1995, Nature Genetics.
[77] M. Dragunow,et al. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.
[78] I. Shoulson,et al. Psychiatric syndromes in Huntington's disease. , 1983, The American journal of psychiatry.
[79] Hongmin Wang,et al. Effects of overexpression of huntingtin proteins on mitochondrial integrity. , 2009, Human molecular genetics.
[80] S. Schiffmann,et al. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat , 2001, Neuroreport.
[81] A. Kent. Huntington's disease. , 2004, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[82] J. Penney,et al. NMDA receptor losses in putamen from patients with Huntington's disease. , 1988, Science.
[83] T. Foroud,et al. Progression of symptoms in the early and middle stages of Huntington disease. , 2001, Archives of neurology.
[84] R. Schwarcz,et al. II: Excitotoxic models for neurodegenerative disorders , 1984 .
[85] K. Trick,et al. Neuro-psychiatric aspects of Huntington's disease. , 1969, Confinia neurologica.
[86] R. D. Hunt,et al. Huntington's dementia. Clinical and neuropsychological features. , 1978, Archives of general psychiatry.
[87] M. Chesselet,et al. Mouse models of Huntington's disease. , 2002, Trends in pharmacological sciences.
[88] P. Harper. The epidemiology of Huntington's disease , 1992, Human Genetics.
[89] J. Olney,et al. Excitotoxicity and the NMDA receptor - still lethal after eight years , 1995, Trends in Neurosciences.
[90] T. Reed,et al. Huntington's chorea in Michigan. I. Demography and genetics. , 1958, American journal of human genetics.
[91] C. Chaloner,et al. Ethics of abortion: the arguments for and against. , 2007, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[92] R. Faull,et al. The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat. , 1993, Progress in brain research.
[93] J. Noth,et al. Language functions in Huntington's disease. , 1988, Brain : a journal of neurology.
[94] M. Folstein,et al. Clinical Assessment of Irritability, Aggression, and Apathy in Huntington and Alzheimer Disease , 1990, The Journal of nervous and mental disease.
[95] B. Engelsen. Neurotransmitter glutamate: its clinical importance , 1986, Acta neurologica Scandinavica.
[96] K. Jacobson,et al. Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.
[97] Claire-Anne Gutekunst,et al. Huntington’s disease , 2007 .
[98] J. Fernández-Ruiz,et al. The endocannabinoid system and Huntington's disease. , 2003, Current Drug Targets - CNS & Neurological Disorders.
[99] O. Andreassen,et al. Malonate and 3‐Nitropropionic Acid Neurotoxicity Are Reduced in Transgenic Mice Expressing a Caspase‐1 Dominant‐Negative Mutant , 2000, Journal of neurochemistry.
[100] J. Cano,et al. Mitochondrial toxins and neurodegenerative diseases. , 2007, Frontiers in bioscience : a journal and virtual library.
[101] A. Joyner,et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. , 1995, Science.
[102] Reed Te,et al. Huntington's chorea in Michigan. I. Demography and genetics. , 1958 .
[103] Enrico Bracci,et al. Dopamine excites fast-spiking interneurons in the striatum. , 2002, Journal of neurophysiology.
[104] J. Caboche,et al. [Role of dopamine in Huntington's disease]. , 2006, Medecine sciences : M/S.
[105] S. Floresco,et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.
[106] A. Santamaría,et al. Integrative hypothesis for Huntington's disease: a brief review of experimental evidence. , 2007, Physiological research.
[107] T W Berger,et al. Presynaptic modulation by GABAB receptors of glutamatergic excitation and GABAergic inhibition of neostriatal neurons. , 1992, Journal of neurophysiology.
[108] Jeffrey H Kordower,et al. Animal models of Huntington's disease. , 2007, ILAR journal.
[109] S. Schiffmann,et al. Distribution of adenosine A2 receptor mRNA in the human brain , 1991, Neuroscience Letters.
[110] K. Dewhurst,et al. Socio-Psychiatric Consequences of Huntington's Disease , 1970, British Journal of Psychiatry.
[111] J. B. Martin,et al. Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.
[112] Antonio Pisani,et al. Receptor Subtypes Involved in the Presynaptic and Postsynaptic Actions of Dopamine on Striatal Interneurons , 2003, The Journal of Neuroscience.
[113] George Smith Gibbes,et al. On Life , 1828, The London medical and physical journal.
[114] S. Browne,et al. Mitochondria and Huntington's Disease Pathogenesis , 2008, Annals of the New York Academy of Sciences.
[115] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[116] S. Skatchkov,et al. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. , 2009, DNA repair.
[117] A. Lundervold,et al. Characteristic patterns of verbal memory function in patients with Huntington's disease. , 1994, Scandinavian journal of psychology.